Printer Friendly

U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS

 BETHESDA, Md., Nov. 24 ~PRNewswire~ -- CEL-SCI Corporation (NASDAQ: CELI) and Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), announced that results of the ongoing Phase I Study in California with HGP-30, a potential AIDS vaccine, were recently reported in "AIDS Research and Human Retroviruses," Volume 8, Number 8, 1992.
 The trial was conducted by Dr. James Kahn, assistant clinical professor of medicine, San Francisco General Hospital, University of California, San Francisco (UCSF). In the paper, the researchers reported that the first 16 healthy volunteers entered into the trial safely tolerated the vaccine with no evidence of significant chemical or hematologic toxicity attributable to the vaccine. Cytoxic T-cell (CTL) responses were observed and, in general, individuals with a CTL response also developed T-cell proliferative responses to HGP-30. Cytotoxic T-cells have the ability to recognize and kill virally infected cells and are therefore essential in eliminating the viral reproduction process.
 The results obtained by Kahn and colleagues support and extend the results obtained in an earlier trial of HGP-30 conducted at St. Stephen's Hospital in London. The U.K. trial was the first AIDS vaccine trial to use a synthetic peptide subunit of the AIDS virus. A previous publication of the London trial results also indicated that HGP-30 is recognized by the immune system and can induce the formation of cytotoxic T-cells (CTL).
 Allan L. Goldstein, Ph.D., professor and chairman of the Department of Biochemistry and Molecular Biology at the George Washington University Medical Center, is head of the U.S. team that developed HGP-30. Goldstein noted: "The team was encouraged by the fact that the HGP-30 formulation was safely tolerated. Some individuals showed T-cell responses including the ability to elicit cytotoxic 'killer' T-cells that are thought to be essential in the elimination of AIDS infected cells."
 HGP-30 differs from other vaccine candidates in that it is a synthetic copy of a region of the p17 core protein of the AIDS virus and not from the envelope of the virus which is known to undergo frequent mutation. It is thought that the p17 core protein is highly conserved from strain to strain.
 The patented rights to HGP-30 are owned by Viral Technologies, Inc. (VTI), a joint venture of CEL-SCI Corporation and Alpha 1 Biomedicals, Inc.
 -0- 11~24~92
 ~CONTACT: Geert Kersten of CEL-SCI Corporation, 703-549-5293, or Judith A. Hautala, Ph.D., Alpha 1 Biomedicals, Inc., 301-564-4400~
 (CELI ALBM)


ST: CEL-SCI Corporation; Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

IH -- DC001 -- 0887 11~24~92 08:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 24, 1992
Words:417
Previous Article:NEIGHBORHOOD PRINT SHOPS BECOMING HIGH-TECH CHRISTMAS GIFT FACTORIES
Next Article:RONALD McDONALD HOUSE FAMILIES KEEP IN TOUCH THANKS TO AT&T FAMILY PHONE
Topics:


Related Articles
THERION BIOLOGICS CORPORATION SIGNS EXCLUSIVE WORLDWIDE AGREEMENT WITH HARVARD MEDICAL SCHOOL FOR NOVEL AIDS VACCINE TECHNOLOGY
THERION BIOLOGICS BEGINS PHASE I CLINICAL TRIAL WITH AIDS VACCINE IN COLLABORATION WITH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
THERION BIOLOGICS RECEIVES $5.0 MIL. GRANT FROM NIAID TO EXPAND AIDS VACCINE DEVELOPMENT PROGRAM; HARVARD LICENSEE RECEIVES $6.0 MIL. GRANT
The Politics of AIDS Vaccines In the Developing World.
CEL-SCI Shareholder Letter.
CEL-SCI Corporation Announces In Vitro Data On Serum Samples From South African AIDS Infected Patients.
FDA APPROVES 1ST TEST OF AIDS VACCINE.
Jag for HIV is just five years off.
WE'RE JUST 5 YEARS AWAY FROM AIDS JAB; Drugs firm offers new hope.
Thai Trial Confirms Earlier Results That VaxGen's AIDSVAX Is Not Efficacious - IAVI Response.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters